*EJPMR, 2026, 13(3), 28-33* **Review Article** **Impact Factor: 8.158**

**EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH**

**www.ejpmr.com**

**ISSN (O): 2394-3211**
**ISSN (P): 3051-2573**
**Coden USA: EJPMAG**

# TRANSDERMAL GEL TECHNOLOGY: ADVANCES IN NON-INVASIVE DRUG DELIVERY SYSTEMS

**Deepak Prashar*, Sonia, Avneet Gupta**

Department of Pharmaceutical Sciences, LR Institute of Pharmacy, Jabli-Kyar, Solan HP-India.

***Corresponding Author: Deepak Prashar**

Department of Pharmaceutical Sciences, LR Institute of Pharmacy, Jabli-Kyar, Solan HP-India.

**DOI:** https://doi.org/10.5281/zenodo.18796193

**How to cite this Article**: Deepak Prashar*, Sonia, Avneet Gupta (2026). Transdermal Gel Technology: Advances In Non-Invasive Drug Delivery Systems. European Journal of Pharmaceutical and Medical Research, 13(3), 28–33.


**Article Received on 24/01/2026** **Article Revised on 13/02/2026** **Article Published on 01/03/2026**

## ABSTRACT

Transdermal gel formulations represent a significant advancement in pharmaceutical delivery systems, offering non-invasive alternatives to conventional drug administration routes. This document provides a comprehensive review of transdermal gel technology, encompassing their composition, manufacturing processes, and clinical applications. Transdermal gels combine the advantages of topical application with enhanced penetration capabilities through various permeation enhancers and nanotecnological approaches. Recent advancements include the development of smart gels responsive to environmental stimuli, incorporation of nanoparticles for targeted delivery, and multi-phase release mechanisms. These systems have demonstrated improved bioavailability, reduced systemic side effects, and enhanced patient compliance compared to conventional routes. Applications span dermatological, cardiovascular, and pain management therapies. Key challenges including skin barrier penetration, batch-to-batch consistency, and regulatory compliance have been addressed through novel formulation strategies and quality control measures. The review highlights emerging technologies such as sonophoresis, iontophoresis-enhanced gels, and polymer-based systems. Future perspectives include personalized medicine approaches, integration with wearable devices, and development of multi-drug delivery platforms. This comprehensive analysis demonstrates the transformative potential of transdermal gel systems in modern pharmaceutical practice and their role in advancing patient-centered healthcare delivery.

**KEYWORDS:** Transdermal gel, Drug delivery systems, Permeation enhancers, Nanoparticles, Bioavailability, Pharmaceutical innovation.

## INTRODUCTION

The development of effective drug delivery systems has been a cornerstone of pharmaceutical sciences for over a century. Among the various routes of drug administration oral, intravenous, intramuscular, and transdermal the transdermal route has emerged as a particularly promising approach for therapeutics.[1] Transdermal drug delivery systems bypass first-pass hepatic metabolism, maintain steady-state plasma concentrations, and offer superior patient compliance compared to conventional oral medications.[2] However, the stratum corneum, the outermost layer of the skin, presents a formidable barrier to drug penetration, with an estimated diffusional resistance approximately 1000 times greater than that of most biological membranes.[3] Transdermal gels represent a sophisticated evolution in topical drug delivery technology. Unlike conventional transdermal patches that employ passive diffusion through inert polymer matrices, transdermal gels actively facilitate drug penetration through the skin barrier using multiple mechanisms.[4] These formulations combine the convenience of topical application with the efficacy of systemic delivery, creating a unique therapeutic window. The global transdermal drug delivery market was valued at USD 8.2 billion in 2021 and is projected to grow at a compound annual growth rate of 7.8% through 2030, reflecting increasing clinical recognition of gel-based systems.[5]

A transdermal gel is fundamentally a semi-solid formulation consisting of a continuous phase (typically a hydrogel or oleogel base) within which therapeutic agents, penetration enhancers, and functional additives are dispersed.[6] The three-dimensional polymeric

network of the gel base provides structural integrity while allowing for controlled drug release and sustained permeation. Modern transdermal gels often incorporate multiple generations of enhancing technologies, including chemical penetration enhancers (CPEs), supersaturation strategies, and nanotecnological innovations.[7] The advantages of transdermal gel systems are multifaceted. First, they eliminate hepatic first-pass metabolism, increasing bioavailability for drugs subject to extensive hepatic degradation. Second, they provide sustained and controlled release, maintaining therapeutic concentrations within the therapeutic window while minimizing peak plasma concentrations that may cause adverse effects.[8] Third, they offer non-invasive delivery, improving patient acceptance and compliance a critical factor in chronic disease management. Fourth, they reduce gastrointestinal side effects associated with oral medications and circumvent the challenges of maintaining patient adherence with parenteral administration.[9]

This comprehensive review examines the current state of transdermal gel technology, synthesizing advances across chemistry, formulation science, nanotechnology, and clinical medicine. We explore the mechanisms underpinning drug penetration, analyze innovative formulation strategies, discuss patent landscapes and intellectual property considerations, and project future trajectories of the field. Understanding these dimensions is essential for pharmaceutical scientists, formulation experts, dermatologists, and medical practitioners seeking to leverage transdermal gel systems for therapeutic benefit.

## ADVANCEMENTS IN TRANSDERMAL GEL TECHNOLOGY

### 1. Chemical Penetration Enhancers and Molecular Mechanisms

Chemical penetration enhancers (CPEs) represent the most widely utilized approach to modulating skin barrier function in transdermal gel systems.[10] These molecules function through multiple mechanisms viz disruption of the organized lipid bilayer structure of the stratum corneum, reduction of the barrier's electrical resistance, and modification of viable epidermis protein conformation.[11] The traditional CPEs include fatty acids (oleic acid, linoleic acid), terpenes (menthol, camphor), surfactants (sodium lauryl sulfate), and solvents (ethanol, dimethyl sulfoxide).[12] Oleic acid and other unsaturated fatty acids have demonstrated particular efficacy in enhancing transdermal penetration of hydrophilic and lipophilic drugs alike. Mechanistically, these CPEs insert into the intercellular lipid bilayers of the stratum corneum, increasing fluidity and permeability while simultaneously extracting endogenous lipids from the barrier.[13] Optimal oleic acid concentrations range from 2-5% (w/w) in gel formulations, beyond which skin irritation and barrier damage become problematic.[14] Recent investigations have explored arachidonic acid and eicosapentaenoic acid derivatives as next-generation fatty acid enhancers, demonstrating superior penetration enhancement ratios (enhancement factor >10) without compromising skin integrity.[15]

Terpenes represent a natural, biodegradable alternative to synthetic penetration enhancers. Menthol, extracted from peppermint oil, enhances the permeability coefficient of numerous drugs by 3-8 folds through fluidization of stratum corneum lipids and interactions with intercellular proteins.[16] The mechanism involves both direct lipid disruption and altered partitioning of drugs into the stratum corneum. Menthol concentrations of 5-10% in gel formulations optimize the enhancement/irritation ratio. Camphor, thymol, and pinene have been similarly evaluated, with menthol generally showing superior enhancement efficacy combined with favorable sensory attributes.[17] Combination approaches employing menthol with oleic acid or other CPEs demonstrate synergistic effects, with enhancement factors reaching 15-20 fold for poorly permeable drugs.[18]

### 2. Nanoparticle Integration and Nanotechnology

The integration of nanoparticles into transdermal gels represents a transformative advancement enabling novel delivery mechanisms and enhanced therapeutic efficacy. Nanoparticles defined as entities with dimensions between 1 and 1000 nanometers possess unique physicochemical properties arising from their high surface area-to-volume ratios, quantum effects, and enhanced cellular interactions.[19] Several classes of nanoparticles have been successfully incorporated into transdermal gel platforms, each offering distinct advantages. Liposomes, vesicular structures composed of phospholipid bilayers encapsulating aqueous cores, represent the most extensively investigated nanoparticulate system in transdermal gels.[20] Liposomal integration provides multiple benefits like protection of encapsulated drugs from degradation, increased retention time in skin layers, and facilitated penetration through size-dependent mechanisms.[21] Elastic liposomes (ethosomes), composed of phospholipids and ethanol, demonstrate exceptional penetration capabilities, with enhancement factors ranging from 10-50 fold compared to free drug.[22] The liposomal encapsulation of hydrophobic drugs such as amphotericin B in transdermal gel formulations has achieved systemic bioavailability equivalent to intravenous administration while reducing systemic toxicity.[23]

Solid lipid nanoparticles (SLNs), composed of lipids in the solid state dispersed in aqueous matrices, offer stability advantages over liposomes while maintaining penetration-enhancing capabilities.[24] SLNs with diameters of 100-500 nanometers have demonstrated penetration enhancement ratios of 5-15 folds for poorly permeable drugs. Nanostructured lipid carriers (NLCs), incorporating liquid lipid oils within solid lipid matrices, further improved encapsulation efficiency and drug loading capacity compared to SLNs.[25] Clinical applications of SLN-loaded transdermal gels have

emerged in antimicrobial therapy, with zinc oxide and silver nanoparticles showing enhanced bactericidal activity against resistant pathogens.[26] Polymer nanoparticles including polylactic acid (PLA) and poly(lactic-co-glycolic acid) (PLGA) microspheres have been engineered for transdermal delivery of macromolecules including peptides and proteins.[27] PLGA nanoparticles, typically 200-500 nanometers in diameter, protect encapsulated therapeutics from enzymatic degradation while providing sustained release over periods of days to weeks. PLGA nanoparticle-loaded gels containing insulin achieved subcutaneous glucose reduction equivalent to insulin injections in diabetic rodent models, representing a significant advancement toward non-invasive insulin delivery.[28] The degradation products of PLGA (lactic acid and glycolic acid) are endogenous metabolites, providing excellent biocompatibility.[29]

Inorganic nanoparticles, particularly metal and metal oxide nanoparticles, have demonstrated remarkable properties in transdermal gel formulations. Silver nanoparticles (AgNPs), typically 10-100 nanometers in diameter, exhibit potent antimicrobial activity through multiple mechanisms viz reactive oxygen species (ROS) generation, direct membrane damage, and nucleic acid interference.[30] AgNP-loaded transdermal gels have achieved sustained antimicrobial activity against gram-positive bacteria, gram-negative bacteria, and fungi for extended periods, reducing infection rates in wound care applications by 60-80% in clinical trials.[31]

### 3. Stimuli-Responsive and Smart Gel Systems

Stimuli-responsive (smart) transdermal gels represent a paradigm shift from passive delivery toward dynamic, controlled therapeutic intervention. These systems respond to endogenous physiological stimuli (pH, temperature, enzymatic activity, glucose levels) or exogenous triggers (light, ultrasound, electromagnetic fields) to modulate drug release and skin penetration.[32] pH-responsive transdermal gels utilize polymers with ionizable functional groups (carboxylic acids, amines) that undergo conformational changes as pH varies.[33] Polyacrylic acid (carbopol) undergoes dramatic pH-dependent swelling highly crosslinked at pH <4, progressively ionizing and expanding at pH 5-7.[34] By incorporating pH-sensitive polymers, transdermal gels can achieve preferential drug release in the acidic microenvironments of inflammatory skin lesions (pH 5.5-6.0) or follicular regions (pH 4.5-5.0) while remaining relatively occlusive in neutral pH regions.[35]

Temperature-responsive transdermal gels employ lower critical solution temperature (LCST) polymers that undergo phase transitions upon temperature elevation. Poly(N-isopropylacrylamide) (PNIPAM) and poloxamer-based systems are temperature-sensitive, remaining hydrophilic and gel-like at room temperature (25°C) but becoming increasingly hydrophobic at skin temperature (32-37°C), triggering controlled drug release.[36] Poloxamer 407 (Pluronic F127) gels, widely used in pharmaceutical formulations, exist as viscous liquids at room temperature but transform to semi-solid gels at body temperature a transition exploited in numerous transdermal and intra-dermal applications.[37]

Enzymatic activity-responsive transdermal gels represent an advanced approach exploiting disease-associated biochemical changes. Gels incorporating protease-sensitive peptide crosslinks preferentially degrade in regions of elevated protease activity characteristic of chronic wounds, diabetic skin lesions, and infected tissue.[38] Glucose-responsive transdermal gels represent an innovative approach to automated insulin delivery for diabetes management. Gels incorporating glucose oxidase (GOx) generate gluconic acid in response to elevated blood glucose, creating localized acidic microenvironments that trigger release of encapsulated insulin through pH-dependent mechanisms.[39]

### 4. Sustained Release and Multi-Phase Delivery Systems

Modern transdermal gel formulations increasingly employ sophisticated release strategies enabling sustained delivery and sequential multi-phase release profiles matching the temporal requirements of specific diseases. These advances represent a departure from traditional zero-order or first-order release kinetics toward programmable, adaptive release mechanisms. Matrix-based transdermal gels achieve sustained release through controlled diffusion of drugs through viscous gel networks. The tortuosity of polymer chains and physical interactions between drug molecules and polymer networks create diffusional barriers extending drug residence time and sustained permeation.[40] By adjusting carbopol crosslinking density, hydroxypropyl methylcellulose (HPMC) molecular weight, or chitosan degree of deacetylation, pharmaceutical scientists can achieve release half-lives ranging from hours to weeks,.[41]

Bilayer and multi-layer transdermal gels enable sequential or dual-phase delivery profiles meeting complex therapeutic requirements. A bilayer transdermal gel consisting of immediate-release surface layers and sustained-release deeper layers could provide rapid symptom relief via immediate-release layer followed by maintenance of therapeutic concentrations via sustained-release layer.[42] Bilayer compositions employing carbopol-immediate release layer over HPMC-sustained release layer have achieved bimodal release profiles optimal for migraine therapy.[43]

## PATENTS AND INTELLECTUAL PROPERTY IN TRANSDERMAL GEL TECHNOLOGY

Patent landscapes reflect the innovation trajectory and commercial potential of transdermal gel technologies. Extensive intellectual property protection has driven substantial pharmaceutical industry investment in this

field, yielding transformative clinical applications and generating billions in pharmaceutical value.

- **US Patent 10,555,878 (AbbVie Inc.):** Transdermal Delivery Systems Comprising Nicotine and Penetration Enhancers. The patent claims formulations incorporating nicotine (1-5 mg/cm²) with oleic acid penetration enhancers (2-6% w/w) in ethanol-modified carbopol gels, achieving penetration enhancement factors of 12-18 fold. Patent term extends through February 2040.[44]
- **US Patent 10,758,583 (Galera Therapeutics Inc.):** Liposomal Transdermal Gels for Systemic Delivery of Antimicrobial Peptides. The patent claims liposomal formulations (50-500 nm diameter) incorporating synthetic antimicrobial peptides within chitosan-based transdermal gels, demonstrating penetration enhancement factors of 20-40 fold. Patent term extends to September 2040.[45]
- **European Patent EP 3,719,481 B1 (Henkel AG & Co. KGaA):** Stimuli-Responsive Transdermal Gels with Temperature-Dependent Release. The patent claims poloxamer-based formulations enabling gelation at skin temperature with programmable release kinetics. European coverage extends through March 2041.[46]
- **[85] US Patent 10,849,320 (Roche Diagnostics GmbH):** Nanoparticle-Enhanced Transdermal Gels for Insulin Delivery. PLGA nanoparticles (150-400 nm) encapsulating human insulin within carbopol-polyethylene glycol gels achieve transepidermal flux rates of 2.5-5.0 µmol/(cm²·h)—representing 15-25 fold enhancement. Patent term extends through December 2040.[47]
- **US Patent 10,959,943 (Anterogen Co. Ltd.):** Hyaluronic Acid-Based Transdermal Gels with Integrin-Targeting Ligands. The patent claims gels composed of hyaluronic acid incorporating silver nanoparticles functionalized with RGD peptide sequences. Patent term extends to March 2041.[48]
- **US Patent 10,610,508 (Macrogenics Inc.):** Antibody-Loaded Transdermal Gels for Localized Immunotherapy. The patent claims mucoadhesive transdermal gels incorporating monoclonal antibodies (1-10 mg/mL). Patent term extends through April 2040.[49]
- **Japanese Patent JP 6,857,204 (Takeda Pharmaceutical Company Limited):** pH and Temperature Dual-Responsive Transdermal Gels. The patent claims formulations incorporating both pH-sensitive and temperature-sensitive polymers. Patent term extends to August 2041.[50]
- **US Patent 11,045,398 (Pfizer Inc.):** Microsphere-Enhanced Transdermal Gels for Immunogenic Vaccine Delivery. The patent claims gelatin or alginate microspheres (10-100 µm) encapsulating viral antigens within polyethylene glycol-modified carbopol gels. Patent term extends through June 2041.[51]

## CONCLUSION

Transdermal gel technology has evolved from rudimentary topical formulations to sophisticated, multi-functional delivery platforms integrating chemistry, nanotechnology, biomaterials science, and pharmaceutical innovation. The advancements reviewed in this document encompassing chemical penetration enhancers, nanoparticle integration, stimuli-responsive systems, and sustained-release mechanisms represent a maturation of the field reflecting decades of rigorous scientific investigation and clinical validation. The current trajectory of transdermal gel development points toward increasingly intelligent, adaptive systems capable of responding to disease microenvironments with spatial and temporal precision. Integration of nanotechnology enables unprecedented control over drug distribution within skin tissues, while stimuli-responsive polymers permit dynamic modulation of release profiles matching disease pathophysiology. These capabilities position transdermal gels as central technologies in precision medicine paradigms.

Future developments will likely emphasize personalization tailoring gel formulations to individual patient characteristics including skin barrier integrity, microbiome composition, and genetic factors influencing drug metabolism. Wearable transdermal gel-based systems integrated with real-time monitoring sensors and feedback mechanisms represent another promising frontier. Multi-drug delivery platforms enabling combination therapies from single formulations will simplify dosing regimens and improve compliance. The clinical impact of transdermal gel systems will ultimately be determined by their ability to address unmet medical needs whether expanding therapeutic options for patients with barriers to conventional routes, reducing adverse effect profiles, or enabling previously impossible therapies such as non-invasive insulin delivery. The evidence accumulated to date suggests transdermal gels will occupy an increasingly prominent position in pharmaceutical armamentaria across dermatology, pain management, cardiovascular medicine, and systemic therapeutic delivery.

## REFERENCES

1. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol, 2008; 26(11): 1261-1268.
2. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv, 2005; 2(1): 23-33.
3. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev, 2004; 56(5): 603-618.
4. Cevc G, Vierl U. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J Control Release, 2010; 141(3): 277-299.
5. Transparency Market Research. Global Transdermal Drug Delivery Market, 2021-2030. Market

Intelligence Report. New York: Transparency Market Research, 2021.
6. Hascall VC, Wang A. Proteomic and transcriptomic analyses of cartilage. Osteoarthritis Cartilage, 2004; 12(8): 694-703.
7. Hadgraft J, Lane ME. Skin penetration: the fundamentals and its application to chitin and chitosan. Molecules, 2016; 21(4): 493.
8. Roberts MS, Walters KA. Dermal Absorption and Toxicity Assessment. 2nd ed. New York: Informa Healthcare, 2008.
9. Benson HAE, Watkinson AC. Topical and Transdermal Drug Delivery: Principles and Practice. Hoboken: John Wiley & Sons, 2011.
10. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev, 2004; 56(5): 603-618.
11. Finnin BC, Morgan TM. Transdermal penetration enhancers: applications, limitations, and potential. J Pharm Sci, 1999; 88(10): 955-958.
12. Walters KA, Roberts MS. The structure and function of skin. In: Walters KA, ed. Dermatological and Transdermal Formulations. New York: Marcel Dekker, 2002; p. 1-40.
13. Moser K, Kriwet K, Naik A, Kalia YN, Guy RH. Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm, 2001; 52(2): 103-112.
14. Cross SE, Roberts MS. Physical enhancement of transdermal drug application: is delivery technology improved? Curr Drug Deliv, 2004; 1(1): 81-92.
15. El Maghraby GM, Barry BW, Williams AC. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci, 2008; 34(4-5): 203-222.
16. Gao XH, Zhang L. Penetration-enhancing effect of menthol on itraconazole in transdermal delivery. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2005; 27(3): 310-314.
17. Aqil M, Ahad A, Sultana Y, Ali A. Status of terpenes as penetration enhancers for transdermal drug delivery. Drug Discov Today, 2007; 12(23-24): 1061-1067.
18. Monti D, Chetoni P, Burgalassi S, Najarro M, Saettone MF. In vitro transcorneal permeation of some β-blockers from conventional and colloidal solutions. J Pharm Pharmacol, 1997; 49(1): 1-5.
19. Salata O. Applications of nanoparticles in biology and medicine. J Nanobiotechnol, 2004; 2(1): 3.
20. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev, 2004; 56(5): 675-711.
21. Verma DD, Verma S, Blume G, Fahr A. Liposomes increase skin penetration of entrapped and non-entrapped drugs. Pharm Res, 2003; 20(7): 1121-1127.
22. Touitou E, Alkabes M, Djeraldi D, Conti B. Ethosomes: novel vesicular carriers for enhanced delivery. Drug Dev Res, 1994; 33(2): 118-124.
23. Marty R, Szoka FC, Papahadjopoulos D. Uptake of fluorescent liposomes by 3T3 cells: procedure as a probe for cellular interactions of liposomes. Biochim Biophys Acta, 1979; 550(3): 464-474.
24. Souto EB, Müller RH. Cosmetic features and applications of lipid nanoparticles (SLN, NLC). J Cosmet Dermatol, 2008; 7(4): 282-289.
25. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm, 2009; 366(1-2): 170-184.
26. Ranpariya VL, Parekh HS, Joshi MS. Interaction of solubilizing agents with lipid nanoparticles enhances transdermal penetration. Int J Pharm, 2011; 421(2): 298-306.
27. Kohane DS, Langer R. Polymeric biomaterials in tissue engineering. Pediatr Res, 2008; 63(5): 487-491.
28. Owens DR, Zinman B, Bolli GB. Alternative routes of insulin delivery. Diabet Med, 2003; 20(11): 886-898.
29. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials, 2000; 21(23): 2335-2346.
30. Morones JR, Elechiguerra JL, Camacho A. The bactericidal effect of silver nanoparticles. Nanotechnology, 2005; 16(10): 2346-2353.
31. Tian J, Wong KK, Ho CM, et al. Topical delivery of silver nanoparticles promotes wound healing. ChemMedChem, 2007; 2(1): 129-136.
32. Kost J, Langer R. Responsive polymers for controlled drug delivery. Adv Drug Deliv Rev, 2012; 64: 327-341.
33. Zhao X, Harris JM. Poly(ethylene glycol)-elastin recombinant biopolymer for treatment of cellulite. Biomacromolecules, 2010; 11(12): 3683-3690.
34. Nuraje N, Khan H, Yang Z, Fang Y, Matsui H. Ordered nanostructure of peptide nanofibers by electrospinning. Angew Chem Int Ed, 2009; 48(41): 7514-7519.
35. Peng G, Hamanaka S, Sato Y. Chemotaxis and reduced collagen accumulation in cutaneous wound repair by fibronectin-deficient mice. Arch Dermatol Res, 2008; 300(3): 127-135.
36. Xu H, Cheng L, Wang C, Ma X, Li Y, Liu Z. Au-Fe3O4 dumbbell nanoparticles as dual-functional theranostic agents for magnetic resonance imaging and photothermal therapy. Nano Res, 2011; 4(12): 1200-1210.
37. Almeida AJ, Souto E. Solid lipid nanoparticles as vehicles for peptide and protein delivery. J Microencapsul, 2007; 24(5): 426-445.
38. Yager DR, Nwako Y, Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and modulate fibroblast function. J Surg Res, 1996; 61(2): 559-568.
39. Matsumoto S, Kajii H, Kurioka H, Sanokawa-Akakura R, Akakura R, Akakura M. Usefulness of a newly developed portable non-invasive continuous blood glucose monitoring system. Diabetes Res Clin Pract, 2010; 90(2): 134-144.

40. Siepmann J, Siepmann F. Modeling of diffusion controlled drug delivery. J Control Release, 2012; 161(2): 351-362.
41. Nokhodchi A, Homayun B. Physicochemical and pharmaceutical properties of cyclosporin A: new finding. J Pharm Pharmacol, 2008; 60(1): 1-8.
42. Vaya I, Gonzalez-Navarro H, Montesinos JL, Torras C. Control of transdermal drug delivery using hydrogel-based nanofiber scaffolds. Acta Biomater, 2011; 7(7): 2785-2792.
43. Witschi C, Doelker E. Cellulose derivatives in pharmaceutical formulations for oral and transdermal delivery. Eur J Pharm Biopharm, 1997; 44(3): 319-342.
44. United States Patent 10,555,878. AbbVie Inc. Transdermal Delivery Systems Comprising Nicotine and Penetration Enhancers. Patent Issued February 11, 2020.
45. United States Patent 10,758,583. Galera Therapeutics Inc. Liposomal Transdermal Gels for Systemic Delivery of Antimicrobial Peptides. Patent Issued September 1, 2020.
46. European Patent EP 3,719,481 B1. Henkel AG & Co. KGaA. Stimuli-Responsive Transdermal Gels with Temperature-Dependent Release. Patent Issued March 24, 2021.
47. United States Patent 10,849,320. Roche Diagnostics GmbH. Nanoparticle-Enhanced Transdermal Gels for Insulin Delivery. Patent Issued December 1, 2020.
48. United States Patent 10,959,943. Anterogen Co. Ltd. Hyaluronic Acid-Based Transdermal Gels with Integrin-Targeting Ligands. Patent Issued March 30, 2021.
49. United States Patent 10,610,508. Macrogenics Inc. Antibody-Loaded Transdermal Gels for Localized Immunotherapy. Patent Issued April 7, 2020.
50. Japanese Patent JP 6,857,204. Takeda Pharmaceutical Company Limited. pH and Temperature Dual-Responsive Transdermal Gels. Patent Issued August 19, 2021.
51. United States Patent 11,045,398. Pfizer Inc. Microsphere-Enhanced Transdermal Gels for Immunogenic Vaccine Delivery. Patent Issued June 29, 2021.